180 Life Sciences Corp. (NASDAQ:ATNF – Get Free Report) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 17,100 shares, a drop of 59.7% from the March 31st total of 42,400 shares. Currently, 3.3% of the shares of the company are short sold. Based on an average daily volume of 103,100 shares, the days-to-cover ratio is presently 0.2 days.
180 Life Sciences Price Performance
180 Life Sciences stock opened at $1.77 on Friday. 180 Life Sciences has a 52-week low of $1.33 and a 52-week high of $27.93. The firm has a 50-day moving average price of $2.86 and a two-hundred day moving average price of $4.69.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in 180 Life Sciences stock. Armistice Capital LLC purchased a new position in 180 Life Sciences Corp. (NASDAQ:ATNF – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 131,000 shares of the company’s stock, valued at approximately $80,000. Armistice Capital LLC owned 2.46% of 180 Life Sciences at the end of the most recent quarter. 4.07% of the stock is owned by hedge funds and other institutional investors.
180 Life Sciences Company Profile
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.
Read More
- Five stocks we like better than 180 Life Sciences
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Semiconductor Shakeout: Finding Potential Amidst Turmoil
- Using the MarketBeat Dividend Tax Calculator
- Hasbro’s Management Made All the Right Calls This Quarter
- What Are Dividends? Buy the Best Dividend Stocks
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
Receive News & Ratings for 180 Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 180 Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
